Background: Factors considered when selecting a diabetes medication for patients with type 2 diabetes (T2D) in clinical practice may differ from those recommended by professional societies.

Objective: To identify factors that play a major role in guiding the selection of diabetes medications in the real world.

Method: We asked 135 physicians [67% Generalists (Internists and General Practitioners) and 33% Specialists (Endocrinologists and Diabetologists) ] in Saudi Arabia to select a diabetes medication they frequently prescribe in certain clinical scenarios. Then we asked them to rank a set of factors as (“Major,” “Minor,” or “Not” a consideration) according to the degree those factors would typically influence their selection of a particular medication.

Results: Sulfonylurea is the most frequently prescribed second-line agent. Majority (89%) reported prescribing GLP-1 receptor agonists (GLP-1 RA) to “50% of their patients with T2D and ischemic heart disease; and over 2/3 prescribe SGLT-2 inhibitors (SGLT-2i) to <50% of their patients with T2D and heart failure. Strikingly, 41% and 32% of the Generalists did NOT rank “Renal benefits” with SGLT-2i and “cardiovascular benefits” with GLP-1 RA, respectively, as “major consideration” when prescribing these agents. Medication cost was ranked as a “major consideration” by 75% of Specialists and 65% of Generalists when prescribing GLP-1 RA, and by 57% of Specialists and 71% Generalists when prescribing SGLT-2i.

Conclusion: Despite the recent advances in diabetes therapy, medication cost and inadequate awareness of the cardiovascular and renal benefits of novel diabetes agents, particularly among non-specialists, remain major barriers to the wide adoption of recommendations from professional societies. Policies to improve access to novel diabetes medications and disseminate the awareness about the evidence-based benefits of these medications are needed

Disclosure

J.A.Abudahesh: None. J.A.Aijebreen: None. D.Z.Alhalees: None. G.Albraithen: None. G.S.Bamogaddam: None. M.Al-sofiani: None.

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.